受三生制药与辉瑞签订超60亿美元大单影响，港股医药板块高开高走，恒生医药ETF（159892）涨超3%，三生制药一度涨超30%，再鼎医药、信达生物等全线大涨。近期受新冠感染率上升等消息影响，医药板块热度显著回升，恒生医药ETF已连续3日上涨，成交持续活跃。财通证券认为，美国“降价”行政令短期对于创新药的扰动已基本出清，叠加年报一季报落幕，医药板块仍在寻找和调整方向进程，可重点持续关注有数据催化的...
Source Link受三生制药与辉瑞签订超60亿美元大单影响，港股医药板块高开高走，恒生医药ETF（159892）涨超3%，三生制药一度涨超30%，再鼎医药、信达生物等全线大涨。近期受新冠感染率上升等消息影响，医药板块热度显著回升，恒生医药ETF已连续3日上涨，成交持续活跃。财通证券认为，美国“降价”行政令短期对于创新药的扰动已基本出清，叠加年报一季报落幕，医药板块仍在寻找和调整方向进程，可重点持续关注有数据催化的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.